Cited by 1,048Metabolism, Diabetes, and CancerPI3K/AKT/mTOR signaling in cancerCancer, Hypoxia, and Metabolism

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells

Open access

Zakikhani, Mahvash, Dowling, Ryan, Fantus, I. George, Sonenberg, Nahum, Pollak, Michael·2006·Cancer Research

Published version of a preprint

Open this paper in CoChat — free account Open PDF

Abstract

Recent population studies provide clues that the use of metformin may be associated with reduced incidence and improved prognosis of certain cancers. This drug is widely used in the treatment of type 2 diabetes, where it is often referred to as an "insulin sensitizer" because it not only lowers blood glucose but also reduces the hyperinsulinemia associated with insulin resistance. As insulin and insulin-like growth factors stimulate proliferation of many normal and transformed cell types, agents that facilitate signaling through these receptors would be expected to enhance proliferation. We show here that metformin acts as a growth inhibitor rather than an insulin sensitizer for epithelial cells. Breast cancer cells can be protected against metformin-induced growth inhibition by small interfering RNA against AMP kinase. This shows that AMP kinase pathway activation by metformin, recently shown to be necessary for metformin inhibition of gluconeogenesis in hepatocytes, is also involved in metformin-induced growth inhibition of epithelial cells. The growth inhibition was associated with decreased mammalian target of rapamycin and S6 kinase activation and a general decrease in mRNA translation. These results provide evidence for a mechanism that may contribute to the antineoplastic effects of metformin suggested by recent population studies and justify further work to explore potential roles for activators of AMP kinase in cancer prevention and treatment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-06-1500

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism
Kahn, B. B., Alquier, T., Carling, D., & Hardie, D. G. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2004.12.003 · Cited by 2,799
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388
The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S.-H., Bardeesy, N., DePinho, R. A., Montminy, M., & Cantley, L. C. (2005) · Science · doi:10.1126/science.1120781 · Cited by 1,950
The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress
Shaw, R. J., Kosmatka, M., Bardeesy, N., Hurley, R. L., Witters, L. A., DePinho, R. A., & Cantley, L. C. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308061100 · Cited by 1,797
A serine/threonine kinase gene defective in Peutz–Jeghers syndrome
Hemminki, A., Markie, D., Tomlinson, I. P. M., Avizienyte, E., Roth, S., Loukola, A., Bignell, G. R., Warren, W., Aminoff, M., Höglund, P., et al. (1998) · Nature · doi:10.1038/34432 · Cited by 1,680
Insulin-like growth factors and neoplasia
Pollak, M., Schernhammer, E. S., & Hankinson, S. E. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1387 · Cited by 1,477
Self-citation
Very high risk of cancer in familial Peutz–Jeghers syndrome
Giardiello, F. M., Brensinger, J. D., Tersmette, A. C., Goodman, S. N., Petersen, G. M., Booker, S. V., Cruz–Correa, M., & Offerhaus, G. J. A. (2000) · Gastroenterology · doi:10.1053/gast.2000.20228 · Cited by 1,435
The LKB1 tumor suppressor negatively regulates mTOR signaling
Shaw, R. J., Bardeesy, N. M., Manning, B. D., Lopez, L. V., Kosmatka, M., DePinho, R. A., & Cantley, L. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.007 · Cited by 1,107
Fasting Insulin and Outcome in Early-Stage Breast Cancer: Results of a Prospective Cohort Study
Goodwin, P. J., Ennis, M., Pritchard, K. I., Trudeau, M. E., Koo, J., Madarnas, Y., Hartwick, W., Hoffman, B., & Hood, N. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.42 · Cited by 978

Show all 20 references

Sorted by citations

Items 401–500 of 1,000

Type 2 Diabetes in Neuroendocrine Tumors: Are Biguanides and Statins Part of the Solution?
Herrera-Martínez, A. D., Pedraza‐Arévalo, S., L‐López, F., Gahete, M. D., Gálvez-Moreno, M. Á., Castano, J. P., & Luque, R. M. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01455 · Cited by 52
Metformin and Cancer Stem Cells: Old Drug, New Targets
Bednar, F., & Simeone, D. M. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-12-0026 · Cited by 51
Biguanides drugs: Past success stories and promising future for drug discovery
Grytsai, O., Myrgorodska, I., Rocchi, S., Ronco, C., & Benhida, R. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113726 · Cited by 51
Hypoxia and Metabolism in Cancer
Bensaad, K., & Harris, A. L. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5915-6_1 · Cited by 49
Molecular Pathways: Preclinical Models and Clinical Trials with Metformin in Breast Cancer
Thompson, A. M. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0354 · Cited by 50
Age-related risk of mortality from bladder cancer in diabetic patients: A 12-year follow-up of a national cohort in Taiwan
Tseng, C., Chong, C., Tseng, C., & Chan, T.-T. (2009) · Annals of Medicine · doi:10.1080/07853890902729778 · Cited by 51
Heme Binding Biguanides Target Cytochrome P450-Dependent Cancer Cell Mitochondria
Guo, Z., Sevrioukova, I. F., Denisov, I. G., Zhang, X., Chiu, T.-L., Thomas, D. G., Hanse, E. A., Cuellar, R. A. D., Grinkova, Y. V., Langenfeld, V. W., et al. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.08.009 · Cited by 54
Aurora-A-mediated phosphorylation of LKB1 compromises LKB1/AMPK signaling axis to facilitate NSCLC growth and migration
Zheng, X., Chi, J., Zhi, J., Zhang, H., Yue, D., Zhao, J., Li, D., Li, Y., Gao, M., & Guo, J. (2017) · Oncogene · doi:10.1038/onc.2017.354 · Cited by 51
A MSN-based tumor-targeted nanoplatform to interfere with lactate metabolism to induce tumor cell acidosis for tumor suppression and anti-metastasis
Chen, Z., Liu, M., Guo, D., Zou, M., Wang, S., Cheng, H. L., Zhong, Z., & Zhang, X. (2020) · Nanoscale · doi:10.1039/c9nr10344a · Cited by 52
Metformin Induces G1 Cell Cycle Arrest and Inhibits Cell Proliferation in Nasopharyngeal Carcinoma Cells
Zhao, L., Wen, Z., Jia, C., Li, M., Luo, S.-Q., & Bai, X. (2011) · The Anatomical Record · doi:10.1002/ar.21283 · Cited by 50
Metformin and cancer: Between the bioenergetic disturbances and the antifolate activity
Jara, J. A., & López‐Muñoz, R. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.06.014 · Cited by 50
Vitamin D3 potentiates the growth inhibitory effects of metformin in DU 145 human prostate cancer cells mediated by AMPK / mTOR signalling pathway
Li, H., Gao, J.-M., Liang, J., Xi, J., Fu, M., & Wu, Y. (2015) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12409 · Cited by 50
Metformin decreases lung cancer risk in diabetic patients in a dose-dependent manner
Tsai, M., Yang, C., Kung, Y.-T., Sheu, C., Shen, Y., Chang, P., Huang, M., & Chiu, H. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.09.012 · Cited by 50
The Effect of Metformin on Mortality Following Cancer among Patients with Diabetes
Lega, I. C., Shah, P. S., Margel, D., Beyene, J., Rochon, P. A., & Lipscombe, L. L. (2014) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-14-0327 · Cited by 53
Diabetes Mellitus and Increased Risk of Cancer: Focus on Metformin and the Insulin Analogs
McFarland, M. S., & Cripps, R. (2010) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.11.1159 · Cited by 50
Reprogramming ovarian and breast cancer cells into non-cancerous cells by low-dose metformin or SN-38 through FOXO3 activation
Hu, T. X., Chung, Y. M., Guan, M., Ma, M., Ma, J., Berek, J. S., & Hu, M. C. ‐. (2014) · Scientific Reports · doi:10.1038/srep05810 · Cited by 50
The Pathway from Diabetes and Obesity to Cancer, on the Route to Targeted Therapy
Gallagher, E. J., Fierz, Y., Ferguson, R. D., & LeRoith, D. (2010) · Endocrine Practice · doi:10.4158/ep10098.ra · Cited by 50
Activation of AMP-Activated Protein Kinase by 3,3′-Diindolylmethane (DIM) Is Associated with Human Prostate Cancer Cell Death In Vitro and In Vivo
Chen, D., Banerjee, S., Cui, Q. C., Kong, D., Sarkar, F. H., & Dou, Q. P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047186 · Cited by 50
Metformin: Its emerging role in oncology
Micić, D., Cvijović, G., Trajković, V., Duntas, L. H., & Polovina, S. P. (2011) · HORMONES · doi:10.14310/horm.2002.1288 · Cited by 48
The bidirectional interation between pancreatic cancer and diabetes
Li, J., Cao, G., Ma, Q., Liu, H., Li, W., & Han, L. (2012) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-10-171 · Cited by 49
Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metformin
Lord, S., Collins, J. M., Cheng, W., Haider, S. A., Wigfield, S., Gaude, E., Fielding, B. A., Pinnick, K. E., Harjes, U., Segaran, A., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0665-5 · Cited by 49
Self-citation
Metformin Does Not Reduce Markers of Cell Proliferation in Esophageal Tissues of Patients With Barrett’s Esophagus
Chak, A., Buttar, N. S., Foster, N. R., Seisler, D. K., Marcon, N. E., Schoen, R. E., Cruz-Correa, M. R., Falk, G. W., Sharma, P., Hur, C., et al. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.08.040 · Cited by 48
Chemopreventive effects of metformin on obesity-associated endometrial proliferation
Zhang, Q., Celestino, J., Schmandt, R. E., McCampbell, A. S., Urbauer, D. L., Meyer, L. A., Burzawa, J. K., Huang, M. S., Yates, M. S., Iglesias, D. A., et al. (2013) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2013.03.008 · Cited by 48
Inhibition of the GTPase Rac1 Mediates the Antimigratory Effects of Metformin in Prostate Cancer Cells
Dirat, B., Ader, I., Golzio, M., Massa, F., Mettouchi, A., Laurent, K., Larbret, F., Malavaud, B. A., Cormont, M., Lemichez, E., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0102 · Cited by 48
Localized multidrug co-delivery by injectable self-crosslinking hydrogel for synergistic combinational chemotherapy
He, M., Sui, J., Chen, Y., Bian, S., Cui, Y., Zhou, C., Sun, Y., Liang, J., Fan, Y., & Zhang, X. (2017) · Journal of Materials Chemistry B · doi:10.1039/c7tb01026e · Cited by 48
Metformin inhibited colitis and colitis-associated cancer (CAC) through protecting mitochondrial structures of colorectal epithelial cells in mice
Wang, S., Cui, S., & Qu, X. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1529108 · Cited by 48
A systematic flux analysis approach to identify metabolic vulnerabilities in human breast cancer cell lines
Martin, S. D., & McGee, S. L. (2019) · Cancer & Metabolism · doi:10.1186/s40170-019-0207-x · Cited by 48
Metformin prevents aggressive ovarian cancer growth driven by high-energy diet: similarity with calorie restriction
Al-Wahab, Z. R., Mert, İ., Tebbe, C., Chhina, J., Hijaz, M., Morris, R. T., Ali‐Fehmi, R., Giri, S., Munkarah, A. R., & Rattan, R. (2015) · Oncotarget · doi:10.18632/oncotarget.3434 · Cited by 47
The effect of metformin on breast cancer outcomes in patients with type 2 diabetes
Oppong, B. A., Pharmer, L. A., Oskar, S., Eaton, A. A., Stempel, M. M., Patil, S. N., & King, T. A. (2014) · Cancer Medicine · doi:10.1002/cam4.259 · Cited by 47
Metformin and the risk of endometrial cancer: A case–control analysis
Becker, C., Jick, S. S., Meier, C. R., & Bodmer, M. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.03.009 · Cited by 48
Carbon Source and Myc Expression Influence the Antiproliferative Actions of Metformin
Javeshghani, S., Zakikhani, M., Austin, S., Bazile, M., Blouin, M., Topisirović, I., St‐Pierre, J., & Pollak, M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2907 · Cited by 49
Self-citation
Increase in apoptosis by combination of metformin with silibinin in human colorectal cancer cells
Tsai, C.-C. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i14.4169 · Cited by 47
AMPK activators suppress breast cancer cell growth by inhibiting DVL3-facilitated Wnt/β-catenin signaling pathway activity
Zou, Y., Xie, C., Yang, S., & Xiong, J. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.6094 · Cited by 47
Estrogen receptor signaling mediates leptin-induced growth of breast cancer cells via autophagy induction
Raut, P. K., Choi, D. Y., Kim, S. H., Hong, J. T., Kwon, T. K., Jeong, J. H., & Park, P. (2017) · Oncotarget · doi:10.18632/oncotarget.22684 · Cited by 48
Mysterious Metformin
Chong, C. R., & Chabner, B. A. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0286 · Cited by 47
Cation-selective transporters are critical to the AMPK-mediated antiproliferative effects of metformin in human breast cancer cells: Transporters in metformin effect against breast cancer cells
Cai, H., Zhang, Y., Han, T. K., Everett, R. S., & Thakker, D. R. (2016) · International Journal of Cancer · doi:10.1002/ijc.29965 · Cited by 46
Metformin Modulates Cyclin D1 and P53 Expression to Inhibit Cell Proliferation and to Induce Apoptosis in Cervical Cancer Cell Lines
Yudhani, R. D., Astuti, I., Mustofa, M., Indarto, D., & Muthmainah, M. (2019) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2019.20.6.1667 · Cited by 49
Therapeutic potential of metformin in papillary thyroid cancer in vitro and in vivo
Cho, S. W., Yi, K. H., Han, S. K., Sun, H. J., Kim, Y. A., Oh, B., Park, Y. J., & Park, D. J. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.05.021 · Cited by 46
Insulin analogues and cancer risk: cause for concern orcause célèbre?
Pollak, M., & Russell-Jones, D. L. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02354.x · Cited by 45
Self-citation
Use of Metformin and Survival of Diabetic Women with Breast Cancer
Peeters, P. J. H. L., Bazelier, M. T., Vestergaard, P., Leufkens, H. G. M., Schmidt, M. K., de Vries, F., & Bruin, M. L. D. (2013) · Current Drug Safety · doi:10.2174/15680266113136660069 · Cited by 46
Inhibition of P42 MAPK Using A Nonviral Vector-Delivered siRNA Potentiates The Anti-Tumor Effect of Metformin in Prostate Cancer Cells
Monteagudo, S., Pérez‐Martínez, F. C., Pérez‐Carrión, M. D., Guerra, J., Merino, S., Sánchez‐Verdú, P., & Ceña, V. (2011) · Nanomedicine · doi:10.2217/nnm.11.61 · Cited by 47
Continuous use of metformin can improve survival in type 2 diabetic patients with ovarian cancer
Wang, S., Lei, K., Liu, J., & Jia, Y. (2017) · Medicine · doi:10.1097/md.0000000000007605 · Cited by 46
Metformin inhibits cervical cancer cell proliferation via decreased AMPK O-GlcNAcylation
Kim, M. Y., Kim, Y. S., Kim, M., Choi, M. Y., Roh, G. S., Lee, D. H., Kim, H. J., Kang, S. S., Cho, G. J., Shin, J. K., et al. (2019) · Animal Cells and Systems · doi:10.1080/19768354.2019.1614092 · Cited by 47
Role of p53 Family Proteins in Metformin Anti-Cancer Activities
Yi, Y., Zhang, W., Yi, J., & Xiao, Z. J. (2019) · Journal of Cancer · doi:10.7150/jca.30659 · Cited by 47
The association between glucose-lowering drug use and mortality among breast cancer patients with type 2 diabetes
Vissers, P. A. J., Cardwell, C. R., van de Poll-Franse, L. V., Young, I. S., Pouwer, F., & Murray, L. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3331-5 · Cited by 45
Curcumin disrupts uterine leiomyosarcoma cells through AKT-mTOR pathway inhibition
Wong, T. F., Takeda, T., Li, B., Tsuiji, K., Kitamura, M., Kondo, A., & Yaegashi, N. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.03.001 · Cited by 45
SUMOylation of AMPKα1 by PIAS4 specifically regulates mTORC1 signalling
Yan, Y., Ollila, S., Wong, I. P. L., Vallenius, T., Palvimo, J. J., Vaahtomeri, K., & Mäkelä, T. P. (2015) · Nature Communications · doi:10.1038/ncomms9979 · Cited by 46
A marine algal polyphenol, dieckol, attenuates blood glucose levels by Akt pathway in alloxan induced hyperglycemia zebrafish model
Kim, E.-A. L., Lee, S., Lee, J., Kang, N., Oh, J.-Y., Seun-heui, S.-H., Ahn, G., Ko, S. C., Fernando, I. P. S., Kim, S.-Y., et al. (2016) · RSC Advances · doi:10.1039/c6ra12724j · Cited by 45
Honokiol induces apoptosis and suppresses migration and invasion of ovarian carcinoma cells via AMPK/mTOR signaling pathway
Lee, J., Sul, J. Y., Park, J. T., Lee, M., Cha, E., & Ko, Y. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4122 · Cited by 45
The relationship between pancreatic cancer and type 2 diabetes: cause and consequence
Li, Y., Bian, X., Wei, S., He, M., & Yang, Y. (2019) · Cancer Management and Research · doi:10.2147/cmar.s211972 · Cited by 49
Insulin, glucose and the increased risk of cancer in patients with type 2 diabetes
Johnson, J. A., & Pollak, M. (2010) · Diabetologia · doi:10.1007/s00125-010-1855-0 · Cited by 48
Self-citation
Breast cancer risk for women with diabetes and the impact of metformin: A meta‐analysis
Lu, Y., Hajjar, A., Cryns, V. L., Trentham‐Dietz, A., Gangnon, R. E., Heckman‐Stoddard, B. M., & Alagöz, O. (2022) · Cancer Medicine · doi:10.1002/cam4.5545 · Cited by 44
Toward Repurposing Metformin as a Precision Anti-Cancer Therapy Using Structural Systems Pharmacology
Hart, T. D., Dider, S., Han, W., Xu, H., Zhao, Z., & Xie, L. (2016) · Scientific Reports · doi:10.1038/srep20441 · Cited by 44
Dialogue Between LKB1 and AMPK: A Hot Topic at the Cellular Pole
Forcet, C., & Billaud, M. (2007) · Science s STKE · doi:10.1126/stke.4042007pe51 · Cited by 48
The Influence of Metformin on IGF-1 Levels in Humans: A Systematic Review and Meta-Analysis
Yang, X., Kord-Varkaneh, H., Talaei, S., Clark, C. C. T., Zanghelini, F., Tan, S. C., Zarezadeh, M., Mousavi, S. M., Rahmani, J., & Zhang, Y. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2019.104588 · Cited by 43
Metformin Accumulation Correlates with Organic Cation Transporter 2 Protein Expression and Predicts Mammary Tumor Regression In Vivo
Checkley, L. A., Rudolph, M. C., Wellberg, E. A., Giles, E. D., Wahdan-Alaswad, R. S., Houck, J. A., Edgerton, S. M., Thor, A. D., Schedin, P., Anderson, S. M., et al. (2017) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-16-0211-t · Cited by 43
Targeting cytochrome P450-dependent cancer cell mitochondria: cancer associated CYPs and where to find them
Guo, Z., Johnson, V., Barrera, J., Porras, M., Ugarte, D. H., Hernández, I., McGarrah, P. W., & Potter, D. A. (2018) · Cancer and Metastasis Reviews · doi:10.1007/s10555-018-9749-6 · Cited by 44
Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer
Rieken, M., Kluth, L. A., Xylinas, E. N., Fajković, H., Becker, A., Karakiewicz, P. I., Herman, M. P., Lotan, Y., Seitz, C., Schramek, P., et al. (2013) · World Journal of Urology · doi:10.1007/s00345-013-1171-7 · Cited by 43
Finasteride Modifies the Relation between Serum C-Peptide and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial
Neuhouser, M. L., Till, C., Kristal, A. R., Goodman, P. J., Hoque, A., Platz, E. A., Hsing, A. W., Albanes, D., Parnes, H. L., & Pollak, M. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-09-0188 · Cited by 42
Self-citation
Anticancer Effects of Metformin and Its Potential Use as a Therapeutic Agent for Breast Cancer
Guppy, A., Jamal‐Hanjani, M., & Pickering, L. M. (2011) · Future Oncology · doi:10.2217/fon.11.49 · Cited by 42
Expanding the therapeutic spectrum of metformin: from diabetes to cancer
Coperchini, F., Leporati, P., Rotondi, M., & Chiovato, L. (2015) · Journal of Endocrinological Investigation · doi:10.1007/s40618-015-0370-z · Cited by 43
Predictive and preventive significance of AMPK activation on hepatocarcinogenesis in patients with liver cirrhosis
Yang, X., Liu, Y., Li, M., Wu, H., Wang, Y., You, Y., Li, P., Ding, X., Liu, C., & Gong, J. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0308-4 · Cited by 43
Inhibition of mTORC1/P70S6K pathway by Metformin synergistically sensitizes Acute Myeloid Leukemia to Ara-C
Yuan, F., Cheng, C., Xiao, F., Liu, H., Cao, S., & Zhou, G. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117276 · Cited by 44
Repurposing of Chronically Used Drugs in Cancer Therapy: A Chance to Grasp
Hijazi, M. A., Gessner, A., & El‐Najjar, N. (2023) · Cancers · doi:10.3390/cancers15123199 · Cited by 44
Effect of Metformin on Viability, Morphology, and Ultrastructure of Mouse Bone Marrow-Derived Multipotent Mesenchymal Stromal Cells and Balb/3T3 Embryonic Fibroblast Cell Line
Śmieszek, A., Czyrek, A. A., Basińska, K., Trynda, J., Skaradzińska, A., Siudzińska, A., Marędziak, M., & Marycz, K. (2015) · BioMed Research International · doi:10.1155/2015/769402 · Cited by 42
Effect of Metformin, Rapamycin, and Their Combination on Growth and Progression of Prostate Tumors in HiMyc Mice
Saha, A., Blando, J. M., Tremmel, L., & DiGiovanni, J. (2015) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-15-0014 · Cited by 43
Specific deletion of AMP-activated protein kinase (α1AMPK) in mouse Sertoli cells modifies germ cell quality
Bertoldo, M. J., Guibert, E., Faure, M., Guillou, F., Ramé, C., Nadal‐Desbarats, L., Foretz, M., Viollet, B., Dupont, J., & Froment, P. (2016) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.01.001 · Cited by 43
Effects and Mechanisms of Metformin on the Proliferation of Esophageal Cancer Cells In Vitro and In Vivo
Tang, J., An, R., Jiang, Y., & Yang, J. (2016) · Cancer Research and Treatment · doi:10.4143/crt.2015.485 · Cited by 42
Metformin: an old drug with new potential
Hajjar, J., Habra, M. A., & Naing, A. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.833604 · Cited by 42
Identification of an Annonaceous Acetogenin Mimetic, AA005, as an AMPK Activator and Autophagy Inducer in Colon Cancer Cells
Liu, Y., Cheng, X., Guo, L.-X., Mao, C., Chen, Y., Liu, H., Xiao, Q., Jiang, S., Yao, Z., & Zhou, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047049 · Cited by 42
The angiotensin II type 1 receptor antagonist telmisartan inhibits cell proliferation and tumor growth of esophageal adenocarcinoma via the AMPKα/mTOR pathwayin vitroandin vivo
Fujihara, S., Morishita, A., Ogawa, K., Tadokoro, T., Chiyo, T., Kato, K., Kobara, H., Mori, H., Iwama, H., & Masaki, T. (2016) · Oncotarget · doi:10.18632/oncotarget.14345 · Cited by 41
The Clinical Effect of Metformin on the Survival of Lung Cancer Patients with Diabetes: A Comprehensive Systematic Review and Meta-analysis of Retrospective Studies
Cao, X., Wen, Z., Wang, X., Li, Y., Liu, K., & Wang, X. (2017) · Journal of Cancer · doi:10.7150/jca.19750 · Cited by 40
Metformin Treatment Inhibits Motility and Invasion of Glioblastoma Cancer Cells
Hassan, M. A., Fakhoury, I., Masri, Z. E., Ghazale, N., Dennaoui, R., Atat, O. E., Kanaan, A., & El‐Sibai, M. (2018) · Analytical Cellular Pathology · doi:10.1155/2018/5917470 · Cited by 44
Repurposing metformin for the treatment of gastrointestinal cancer
Júnior, A. D. D. C., Bragagnoli, A. S. C., Costa, F. O., & Carvalheira, J. B. C. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i17.1883 · Cited by 42
W arburg effect regulated by amphiregulin in the development of colorectal cancer
Nam, S. O., Yotsumoto, F., Miyata, K., Fukagawa, S., Yamada, H., Kuroki, M., & Miyamoto, S. (2015) · Cancer Medicine · doi:10.1002/cam4.416 · Cited by 44
Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor?
Stambolic, V., Woodgett, J. R., Fantus, I. G., Pritchard, K. I., & Goodwin, P. J. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0015-4 · Cited by 41
Self-citation
Inhibition of Polo-like Kinase 1 (Plk1) Enhances the Antineoplastic Activity of Metformin in Prostate Cancer
Shao, C., Ahmad, N., Hodges, K. B., Kuang, S., Ratliff, T., & Liu, X. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.596817 · Cited by 42
Metformin Inhibits Growth of Hepatocellular Carcinoma Cells by Inducing Apoptosis Via Mitochondrion-mediated Pathway
Xiong, Y., Lu, Q., Zhao, J., & Wu, G. (2012) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2012.13.7.3275 · Cited by 39
Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines
Kim, J., Lee, J., Jang, S. Y., Kim, C., Choi, Y.-J., & Kim, A. (2016) · Oncology Reports · doi:10.3892/or.2016.4675 · Cited by 41
Pharmacometabolomic Assessment of Metformin in Non-diabetic, African Americans
Rotroff, D. M., Oki, N. O., Liang, X., Yee, S. W., STOCKER, S. L., Corum, D. G., Balik-Meisner, M. R., Fiehn, O., Motsinger‐Reif, A. A., Giacomini, K. M., et al. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00135 · Cited by 38
Metformin as a new anti-cancer drug in adrenocortical carcinoma
Poli, G., Cantini, G., Armignacco, R., Fucci, R., Santi, R., Canu, L., Nesi, G., Mannelli, M., & Luconi, M. (2016) · Oncotarget · doi:10.18632/oncotarget.10421 · Cited by 40
Metformin Promotes AMP-activated Protein Kinase-independent Suppression of ΔNp63α Protein Expression and Inhibits Cancer Cell Viability
Yi, Y., Chen, D., Ao, J., Sun, S., Wu, M. C., Li, X., Bergholz, J. S., Zhang, Y., & Xiao, Z. J. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.769141 · Cited by 40
Metabolomics profiling of metformin-mediated metabolic reprogramming bypassing AMPKα
Yan, M., Qi, H., Xia, T., Zhao, X., Wang, W., Wang, Z., Lu, C., Ning, Z., Chen, H., Li, T., et al. (2018) · Metabolism · doi:10.1016/j.metabol.2018.11.010 · Cited by 40
Recent advances of mitochondrial complex I inhibitors for cancer therapy: Current status and future perspectives
Zhou, Y., Zou, J., Xu, J. B., Zhou, Y., Cen, X., & Zhao, Y. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115219 · Cited by 43
Effects of Metformin Dose on Cancer Risk Reduction in Patients with Type 2 Diabetes Mellitus: A 6‐Year Follow‐up Study
Lin, H., Kachingwe, B. H., Lin, H., Cheng, H. W., Uang, Y., & Wang, L. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1334 · Cited by 39
Can metformin change the prognosis of pancreatic cancer? Retrospective study for pancreatic cancer patients with pre-existing diabetes mellitus type 2
Lee, S. H., Yoon, S. H., Lee, H. S., Chung, M. J., Park, J. Y., Park, S. W., Song, S. Y., Chung, J. B., & Bang, S. (2015) · Digestive and Liver Disease · doi:10.1016/j.dld.2015.12.006 · Cited by 39
Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers
Khawaja, M. R., Nick, A. M., Madhusudanannair, V., Fu, S., Hong, D. S., McQuinn, L., Ng, C. S., Piha-Paul, S. A., Jankú, F., Subbiah, V., et al. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3009-7 · Cited by 40
Effects of metformin on the PI3K/AKT/FOXO1 pathway in anaplastic thyroid Cancer cell lines
Nozhat, Z., Mohammadi‐Yeganeh, S., Azizi, F., Zarkesh, M., & Hedayati, M. (2018) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-018-0208-2 · Cited by 40
Implications of metabolism-driven myeloid dysfunctions in cancer therapy
Strauss, L., Guarneri, V., Gennari, A., & Sica, A. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00556-w · Cited by 39
Anticancer Properties of Pomolic Acid-Induced AMP-Activated Protein Kinase Activation in MCF7 Human Breast Cancer Cells
Youn, S. H., Lee, J., Lee, M. S., Cha, E. Y., Thương, P. T., Kim, J. R., & Chang, E. S. (2012) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.35.105 · Cited by 38
Metformin inhibits proliferation of human keratinocytes through a mechanism associated with activation of the MAPK signaling pathway
LI, W., Ma, W., ZHONG, H., Liu, W., & Sun, Q. (2013) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2013.1416 · Cited by 39
The hallmarks of premalignant conditions: a molecular basis for cancer prevention
Ryan, B. M., & Faupel‐Badger, J. M. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.007 · Cited by 40
Does Metformin affect ER, PR, IGF-1R, β-catenin and PAX-2 expression in women with diabetes mellitus and endometrial cancer?
Markowska, A., Pawałowska, M., Filas, V., Korski, K., Gryboś, M., Sajdak, S., Olejek, A., Bednarek, W., Śpiewankiewicz, B., Lubin, J., et al. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-76 · Cited by 38
Managing lipid metabolism in proliferating cells: New perspective for metformin usage in cancer therapy
Lettieri‐Barbato, D., Vegliante, R., Desideri, E., & Ciriolo, M. R. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.02.003 · Cited by 39
Metformin confers risk reduction for developing hepatocellular carcinoma recurrence after liver resection
Chan, K., Kuo, C., Hsu, J., Chiou, M., Wang, Y., Wu, T., Lee, C., Wu, T.-J., Chou, H., & Lee, W. (2016) · Liver International · doi:10.1111/liv.13280 · Cited by 38
A review for clinicians: Prostate cancer and the antineoplastic properties of metformin
Hankinson, S. J., Fam, M. M., & Patel, N. N. (2016) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2016.10.009 · Cited by 40
Effects of dichloroacetate as single agent or in combination with GW6471 and metformin in paraganglioma cells
Florio, R., Lellis, L. D., Veschi, S., Verginelli, F., di Giacomo, V., Gallorini, M., Perconti, S., Sanna, M., Mariani‐Costantini, R., Natale, A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-31797-5 · Cited by 37
Phase 1 Study of Erlotinib and Metformin in Metastatic Triple-Negative Breast Cancer
Fenn, K. M., Maurer, M., Lee, S. M., Crew, K. D., Trivedi, M. S., Accordino, M. K., Hershman, D. L., & Kalinsky, K. M. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.08.004 · Cited by 40
Effects of metformin and pioglitazone combination on apoptosis and AMPK/mTOR signaling pathway in human anaplastic thyroid cancer cells
Kutbay, N. Ö., Avcı, Ç. B., Yürekli, B. Ş., Kurt, C. Ç., Shademan, B., Gündüz, C., & Erdoğan, M. (2020) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22547 · Cited by 39
Metformin induces an intracellular reductive state that protects oesophageal squamous cell carcinoma cells against cisplatin but not copper-bis(thiosemicarbazones)
Damelin, L. H., Jivan, R., Veale, R. B., Rousseau, A. L., & Mavri‐Damelin, D. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-314 · Cited by 38

Authors: Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N., & Pollak, M.
Affiliations: 1Oncology and Departments of
McGill University (CA)
Mount Sinai Hospital (CA)
ORCID: Dowling, Ryan
Sonenberg, Nahum
Venue: Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2006-11-01
Volume: 66
Issue: 21
Pages: 10269-10273
ISSN: 0008-5472 (ISSN-L)
1538-7445
DOI: 10.1158/0008-5472.can-06-1500
OpenAlex: W2078190084
Cited by: 1,048
References: 20
Citations by year: 2026: 13 · 2025: 11 · 2024: 24 · 2023: 29 · 2022: 28 · 2021: 54 · 2020: 47 · 2019: 62 · 2018: 55 · 2017: 70 · 2016: 70 · 2015: 80 · 2014: 93 · 2013: 86 · 2012: 85
FWCI: 12.76
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Cancer Research (publishedVersion)
PubMed (publishedVersion)
eScholarship@McGill (McGill) (submittedVersion)
Funders: Canadian Breast Cancer Research Alliance
Terry Fox Foundation
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Keywords: metformin, AMP kinase, breast cancer, cell growth inhibition, antineoplastic effects, mTOR, S6 kinase, mRNA translation, insulin resistance, insulin-like growth factor, epithelial cells, cancer prevention
MeSH terms: Adenylate Kinase, Antineoplastic Agents, Breast Neoplasms, Female, Humans, Insulin, Metformin, Protein Biosynthesis, Gene Expression Regulation, Enzymologic, RNA, Small Interfering, Cell Line, Tumor, Cell Proliferation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks